Prosecution Insights
Last updated: April 19, 2026
Application No. 17/596,988

COMPOUNDS FOR TREATMENT OF CANCER

Final Rejection §112§DP
Filed
Dec 22, 2021
Examiner
DAHLIN, HEATHER RAQUEL
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sinopsee Therapeutics
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
3y 5m
To Grant
97%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
61 granted / 133 resolved
-14.1% vs TC avg
Strong +51% interview lift
Without
With
+50.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
83 currently pending
Career history
216
Total Applications
across all art units

Statute-Specific Performance

§101
4.6%
-35.4% vs TC avg
§103
33.3%
-6.7% vs TC avg
§102
19.8%
-20.2% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 133 resolved cases

Office Action

§112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This Application is a 371 of PCT/SG2020/050362, filed 06/25/2020, and claims foreign priority to SG10201905890P, filed 06/25/2019 in Singapore. Claim Status Claims 23, 26-31, 33-39 and 42 are currently active and subject to examination. Claim 41 is withdrawn pursuant to the Election made by the Applicant in the Remarks dated Feb. 19, 2025. Claim Objections- Maintained Claims 23, 29 and 38-39 are objected to because of the following informalities: the oxygen appears to be missing in this group in claims 23 and 29: PNG media_image1.png 134 195 media_image1.png Greyscale . In claim 38, the structures are not drawn with sufficiently black and clear lines and atom labels: PNG media_image2.png 365 554 media_image2.png Greyscale PNG media_image3.png 553 626 media_image3.png Greyscale PNG media_image4.png 389 620 media_image4.png Greyscale Claim 38. PNG media_image5.png 615 474 media_image5.png Greyscale PNG media_image6.png 678 595 media_image6.png Greyscale PNG media_image7.png 863 521 media_image7.png Greyscale Claim 39. Appropriate correction is required. Specification A substitute specification including the claims is required pursuant to 37 CFR 1.125(a) because (A) the structures in claims 38-49 are not drawn with sufficiently black and clear lines and atom labels; (B) the structures on pages 15-19, 30-34, 64-68 and 80-87 are not drawn with sufficiently black and clear lines and atom labels. The numerous illegible structures and labels make it difficult to consider the application. For example: PNG media_image8.png 348 520 media_image8.png Greyscale p. 15; PNG media_image9.png 634 668 media_image9.png Greyscale p. 16; PNG media_image10.png 268 612 media_image10.png Greyscale p. 17; PNG media_image11.png 871 470 media_image11.png Greyscale p. 18; PNG media_image12.png 661 448 media_image12.png Greyscale p. 19; PNG media_image13.png 676 615 media_image13.png Greyscale p. 30; PNG media_image14.png 530 603 media_image14.png Greyscale p. 31; PNG media_image15.png 358 510 media_image15.png Greyscale p. 32; PNG media_image16.png 298 637 media_image16.png Greyscale p. 33; PNG media_image17.png 612 620 media_image17.png Greyscale p. 34; PNG media_image18.png 326 519 media_image18.png Greyscale p. 64; PNG media_image19.png 863 611 media_image19.png Greyscale p. 65; PNG media_image20.png 480 454 media_image20.png Greyscale p. 66; PNG media_image21.png 837 486 media_image21.png Greyscale p. 67; PNG media_image22.png 364 461 media_image22.png Greyscale p. 68; PNG media_image23.png 138 523 media_image23.png Greyscale p. 80. PNG media_image24.png 855 412 media_image24.png Greyscale p. 81; PNG media_image25.png 653 588 media_image25.png Greyscale p. 82; PNG media_image26.png 276 622 media_image26.png Greyscale p. 83; PNG media_image27.png 185 632 media_image27.png Greyscale PNG media_image28.png 243 568 media_image28.png Greyscale p. 85; PNG media_image29.png 317 638 media_image29.png Greyscale p. 86; PNG media_image30.png 585 648 media_image30.png Greyscale p. 87. The above are presented as examples. Applicant should examine each structure in the Specification for legibility and clarity and correct as required by providing structures with sufficiently dark and clear lines and letters. A substitute specification must not contain new matter. The substitute specification must be submitted with markings showing all the changes relative to the immediate prior version of the specification of record. The text of any added subject matter must be shown by underlining the added text. The text of any deleted matter must be shown by strike-through except that double brackets placed before and after the deleted characters may be used to show deletion of five or fewer consecutive characters. The text of any deleted subject matter must be shown by being placed within double brackets if strike-through cannot be easily perceived. An accompanying clean version (without markings) and a statement that the substitute specification contains no new matter must also be supplied. Numbering the paragraphs of the specification of record is not considered a change that must be shown. Claim Rejections- Withdrawn- Overcome by Amendment The rejection of claims 23-40 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being is withdrawn. The rejection of claims 27-28, 34 and 40 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form is withdrawn. The rejection of claims 23-25, 27, 29, 30, 32, 33, 35 and 42 under 35 U.S.C. 102(a)(1) as being anticipated by Cheng et al. (WO 2015043492 A1; of record IDS cite no. 1) is withdrawn. The rejection of claims 23-24, 27, 29, 30, 32, 33, 35, 40 and 42 under 35 U.S.C. 102(a)(1) as being anticipated by Barda et al. (US 7,666,879 B2) is withdrawn. The rejection of claim(s) 23, 24, 25, 29, 30, 32, 33, 35, 37, and 42 under 35 U.S.C. 103 as being unpatentable over Cherian et al. (WO 2014088519 A1; of record IDS cite no. 8) is withdrawn. The rejection of claim(s) 23, 24, 25, 29, 30, 32, 33, 35, 37, and 42 under 35 U.S.C. 103 as being unpatentable over Chen et al. (US 7,709,518 B2) is withdrawn. The above rejections were overcome by Applicant’s amendments. Claim Rejections - 35 USC § 112(b)- New Grounds of Rejection Necessitated by Amendment The following is a quotation of 35 U.S.C. 112(b): “(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.” The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: “The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.” Claims 26 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. One of ordinary skill in the art cannot determine the metes and bounds of claim 26 because it is unclear what alternatives are covered by the claim. The claim recites that each R1 to R5 is halo or C1-3 alkyl, optionally wherein each R1 to R5 is fluoro, chloro, methyl or ethyl. It is unclear how these optional groups are further limiting to the claim, and if they are meant to specify a further limitation of the claim. Examples and preferences are properly set forth in the specification (MPEP 2173.05(d)). Appropriate correction is required. Claim Rejections - 35 USC § 112(d)- New Grounds of Rejection Necessitated by Amendment The following is a quotation of 35 U.S.C. 112(d): “(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.” The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: “Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.” Claims 38-39 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 38-39 fail to include all of the limitations of claim 23 upon which they depend. Claim 23 requires that Z is attached to the molecule by a covalent bond but claims 38-39 have several molecules wherein Z is not attached by a covalent bond, but rather through O or NH: PNG media_image31.png 399 796 media_image31.png Greyscale PNG media_image32.png 325 813 media_image32.png Greyscale Claim 38; PNG media_image33.png 251 421 media_image33.png Greyscale Claim 39. Applicant may cancel the claim(s), amend the , claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Statutory Double Patenting- Previously Presented A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. The provisional rejection of claims 23 and 33-35 under 35 U.S.C. 101 as claiming the same invention as that of claims 21, 24-33 and 38 of copending Application No. 17/596,976 (reference application) is maintained. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Response to Arguments The Applicant did not traverse the rejection but merely requested that it be held in abeyance (Remarks, p. 39). As such, the rejection is maintained. Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. The provisional rejection of claims 23, 26-31, 33-39 and 42 on the ground of nonstatutory double patenting as being unpatentable over claims 21, 24-33, 38 and 40 of copending Application No. 17/596,976 is maintained. Both claims are directed towards the same genus of compounds and list overlapping species. This is a provisional nonstatutory double patenting rejection. Response to Arguments The Applicant did not traverse the rejection but merely requested that it be held in abeyance (Remarks, p. 39). As such, the rejection is maintained. Conclusion No claim is found to be allowable. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HEATHER DAHLIN whose telephone number is (571)270-0436. The examiner can normally be reached 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on (571) 272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 86-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HEATHER DAHLIN/Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Dec 22, 2021
Application Filed
Apr 04, 2025
Non-Final Rejection — §112, §DP
Oct 09, 2025
Response after Non-Final Action
Oct 09, 2025
Response Filed
Nov 11, 2025
Response Filed
Dec 17, 2025
Final Rejection — §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600727
TREATMENT OF INFECTIONS OF TOXOPLASMA GONDII AND CLOSELY RELATED PARASITES
2y 5m to grant Granted Apr 14, 2026
Patent 12595262
PRMT5 INHIBITORS
2y 5m to grant Granted Apr 07, 2026
Patent 12583860
Processes for the Preparation of Multicomponent Crystalline Forms of Active Pharmaceutical Ingredients Using Solvent Vapour
2y 5m to grant Granted Mar 24, 2026
Patent 12583835
CRYSTAL FORM OF NITROXOLINE PRODRUG, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12576091
PREPARATION METHOD OF SALFAPRODIL FREEZE-DRIED POWDER INJECTION, AND PRODUCT AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
97%
With Interview (+50.7%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 133 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month